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ABSTRACT: Antagonism of DvE6 is emerging as a potential treatment of idiopathic pulmonary fibrosis based on strong target val-
idation. Starting from an DvE3 antagonist lead and through simple variation in the nature and position of aryl substituent, the dis-
covery of compounds with improved DvE6 activity is described. The compounds also have physicochemical properties commensu-
rate with oral bioavailability and are high quality starting points for a drug discovery programme. Compounds 33S and 43E1 are
pan Dv antagonists having ca 100 nM potency against DvE3, DvE5, DvE6 and DvE8 in cell adhesion assays. Detailed structure activity
relationships with these integrins are described which also reveal substituents providing partial selectivity (defined as at least a 0.7
log difference in pIC50 values between the integrins in question) for DvE3 and DvE5.
Once diagnosed, life expectancy for patients with idiopathic
pulmonary fibrosis (IPF) is usually only a few years and the
mortality rate exceeds that of many cancer indications.
1,2
A
recent study in the UK also suggests that the incidence of IPF
is rising with > 5,000 new cases diagnosed each year.
3
Alt-
hough pirfenidone is now marketed for the treatment of IPF in
some countries,
4
there remains an urgent need for effective
new medicines. Recent research into IPF together with esti-
mated peak sales for an effective treatment at around $2 bil-
lion per annum, have driven significant commercial activity
around potential biological and small molecule fibrosis assets
in the pharmaceutical sector.
5
There is now reasonable evidence that the RGD (arginine-
glycine-aspartic acid) integrin receptor DvE6 may play an im-
portant role in the initiation and progression of IPF inter
alia.
6,7
This receptor is predominantly expressed in injured
lung tissue and inhibition of the receptor with DvE6 antibodies
or its absence in knock-out mice leads to substantial protection
from the development of fibrosis in both bleomycin
8
and ra-
diation
9
induced animal models. Selective DvE6 antibodies are
in development for fibrotic diseases.
5
The DvE6 receptor is a cell surface heterodimeric receptor
composed of a non-covalently bound complex between the Dv
and E6 proteins. Three closely related integrins where only the
E subunit is varied are DvE3,DvE5 andDvE8. Despite substantial
research and drug discovery over the last decade on antago-
nists of the DvE3 receptor for osteoporosis and other indica-
tions,
10-13
there is remarkably little literature on potent and
selective small molecule antagonists of DvE6. The selectivity
profiles of the DvE3 antagonists in the literature rarely include
cross-screening data against DvE6 or other Dv integrins with the
exception of a Pfizer series of compounds for which a broad
range of integrin data is reported (although the potencies are
quite weak as DvE6 antagonists).14 Other exceptions are the
Merck KGa,
15
Merck AG,
16
Merck,
17
Monsanto
18
compounds
(14, Figure 1) and JNJ-2607671319 (where the Arg guanidine
and Asp acid mimetics are apparent at the either end of a
chain) and very recently Dv integrin data in patents from Ru-
minski and Griggs at the University of St Louis.
20
We describe here detailed structure activity relationship (SAR)
studies of novel analogues of 4 describing for the first time
their profiles against DvE3, DvE5, DvE6 and DvE8 in cell adhesion
assays. By varying the substituent pattern on the aryl ring, we
have discovered pan Dv antagonists such as 33S and 43E1
(pan defined here as having antagonism against all the Dv
integrins tested, namely DvE3, DvE5, DvE6 and DvE8), antagonists
with partial selectivity (defined as at least a 0.7 log difference
in pIC50 values between the integrins in question) for DvE3
(such as 27) and partial selectivity for DvE5 (such as 35). The
profiles of antagonists with partial dual selectivity for DvE3 and
DvE5 (such as the known compounds 417 and 4217) and are also
described. Seemingly fairly subtle changes on just the aryl
ring of the structures exert a profound effect on the overall
selectivity profile, and in this series, it appears considerably
more marked than in the Merck KGa series.
15
Measured lipo-
philicity values for compounds (chrom. logD)
21
are also pro-
vided. (When the sum of chrom. log D plus aromatic ring
count is <6, there is an increased likelihood of a compound
being more developable as an oral drug).
21
2Figure 1. Exemplar Dv integrin antagonists from the literature
together with selected reported activities and activities in the
assays described herein.
The combination of the DvE6 activity of these compounds with
their physicochemical properties, which are commensurate
with potential oral bioavailability, identifies them as high
quality starting points for a drug discovery programme and
amongst the best currently known in the literature.
Derivatives of ethyl or methyl 3-amino-3-phenylpropanoate 7
were prepared in two steps from the appropriate aldehydes 5
by the Rodionov reaction
22
followed by esterification to 7, or
were purchased from commercial sources (Scheme 1). Ethyl
3-amino-3-(3-pyridyl)propanoate 10 was made in the same
way from 3-formylpyridine. Indane-5-carboxaldehyde was
prepared in 38% yield by treatment of indane with hexameth-
ylenetetramine/TFA as described by Arora, et al.
23
Hydrogenation of amino ester hydrochloride 7 (R = H) gave
the cyclohexyl derivative 8. The 4-cyano analogue 7 (R = 4-
CN) was obtained in low yield after the esterification owing to
a competing Pinner reaction. To circumvent this problem in
the case of the 3-cyano analogue, the amino group was pro-
tected as the benzyl carbamate (CBZ), followed by esterifica-
tion under mildly basic conditions and CBZ-group deprotec-
tion to give 9.
Scheme 1. Synthesis of 3-aryl-3-aminopropanoic ester
intermediates.
Reagents and conditions. a: malonic acid, ammonium acetate,
MeOH or EtOH or iPrOH, reflux; b: SOCl2฀,฀ ฀E฀t฀O฀H฀,฀ ฀−฀1฀5฀ qC then
reflux; c: H2 (4 bar), 5% Rh/Al2O3, EtOH, 80 qC; d: N-
(benzyloxycarbonyloxy)succinimide, EtNPri2, CH2Cl2, room
temp., 2 h; e: N,N-carbonyldiimidazole, THF, room temp., then
EtOH; f: H2 (1 bar), 10% Pd/C, EtOH, room temp., 24 h. All
compounds are racemic unless indicated in the text.
Amide coupling of 1,8-naphthyridin-2-yl)pentanoic acid 11
17
to amino esters 7 (R = 2-OMe, 3-Me, 3-OCF3 and 3,4-(OMe)2,
Scheme 2) gave the corresponding esters 12 in 31-67% yields.
Selective hydrogenation of the naphthyridine ring gave the
corresponding compounds 13 (R = 2-OMe, 3-Me, 3-OCF3 and
3,4-(OMe)2) (44-96%). For all the other compounds, the tet-
rahydronaphthyridine pentanoic acid 14
17
could be coupled
directly to the amino esters 7-9 to give compounds 13. Hy-
drolysis of the esters 13 under basic conditions then afforded
the target acids (see Table 1 for numbering).
For the preparation of the single enantiomers of 33, commer-
cially available assigned (R) and (S) enantiomers of the 3-CF3
amino ester 7 were used. For the enantiomers of 37 and 43,
the precursor ethyl esters 13 (R = 3,5-Cl2 and 3-CF3,4-Cl re-
spectively) were separated by preparative chiral HPLC and
then hydrolysed to afford the target compounds.
The compounds were tested in DvE6, DvE3, DvE5 and DvE8 cell
adhesion assays as previously described.
24
Lipophilicity was
determined using an HPLC chromatographic logD protocol.
21
Preliminary unpublished work led to the selection of template
4 as suitable for exploring DvE6 activity and in particular in-
vestigating what the impact of different aryl substituents might
be. Although structure activity relationships (SAR) have been
described by Merck for this template,
17
these predominantly
relate to DvE3 with little, if any, DvE6 data published. Data
from the present study are presented in Table 1. In order to
establish preliminary Dv SAR rapidly, fluoro, chloro, methyl
and methoxy analogues were prepared in the ortho, meta and
para positions.
The parent phenyl compound 15 is a micromolar DvE6 antago-
nist and substantially more potent against DvE3 and DvE5.25,26
In every case, the fluoro, chloro, methyl and methoxy com-
pounds are similarly more potent against DvE3 and DvE5 than
DvE6with activity against DvE8 being similar to or less than the
DvE6 values. The DvE3 and DvE5 values are generally similar to
each other. The superior antagonism against DvE3 is perhaps
unsurprising given the series emanates from one designed as
DvE3 antagonists.
The SARs are idiosyncratic although there are compounds
with approximately 10-fold selectivity for DvE3 and DvE5 over
DvE6 and DvE8 such as R = H (15), m-F (4), m-OMe (22) and p-
OMe (26). More intriguingly perhaps, given the relative lack
of such compounds in the literature, some show suggestions of
selectivity for DvE5 with the o-F (16), m-Cl (20) and the m-Me
(21) having 0.5 log selectivity over DvE3 and about a log selec-
tivity over DvE6 and DvE8. Recent studies suggest there may be
a role for DvE5 antagonists in the treatment of sepsis.27 Based
on these data, the next iteration of analogues focussed on fur-
ther mono-substituents in the meta and para positions as these
showed more consistent DvE6 activity and are more syntheti-
cally accessible compared to the ortho analogues.
Data from further mono-para substituents were explored (Ta-
ble 1, 27χ31). Activities against DvE6 are similar (pIC50
6.16.4) despite varying size and electronic properties. In
contrast, there is a ten-fold range in activity against DvE3
(pIC50 6.67.6) with a p-OMe 26 showing the most potent
activity and a pCF3 28 the least suggesting the electronic
properties of the substituent may play a role.
3Scheme 2. Synthesis of integrin antagonists.
Reagents and conditions. (a) N-(3-dimethylaminopropyl)-Nƍ฀-฀e฀t฀h฀y฀l฀c฀a฀r฀b฀o฀d฀i฀i฀m฀i฀d฀e฀,฀ N-methylm rpholine, 1-hydroxybenzotriazole hydrate,
20 qC; (b) H2 (1 bar), 10% Pd/C, EtOH, 20 qC; (c) 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hex-
afluorophosphate, Et3N, CH2Cl2, room temp.; (d) NaOH(aq.), EtOH, 20 qC; (e) LiOH, THF/H2O, 20 qC. All compounds are racemic unless
indicated in the text.
A similar pattern is seen with DvE5 whereas antagonism of
DvE8 is flat and essentially similar to DvE6. The p-CN analogue
27 suggests some selectivity for DvE3. However these data do
not indicate mono substitution in the para position is useful
for increasing DvE6 activity and so no further analogues were
prepared.
In contrast, mono-substitution in the meta-position (Table 1,
32χ34) proved to be more influential on DvE6 antagonism with
around a tenfold range of activity (pIC50 6.17.1). The size of
the substituent is more influential (compare m-F 4 (pIC50 6.1)
with m-CF3 33 (pIC50 7.0)) than electronic properties (compare
m-MeO 22 and m-Me 21 with m-CN 32 and m-Cl 20 (pIC50
values of 6.5 and 6.4 vs 6.6 and 6.6 respectively)). The enan-
tiomers of the most potent m-CF3 analogue 33 (racemate pIC50
7.0) were prepared from commercially available pure (S) and
(R) enantiomers of 7 thus allowing 33S and 33R to be as-
signed as the (S) and (R) trifluoromethyl enantiomers respec-
tively and with corresponding DvE6 pIC50 values of 7.1 and
5.2. Given the high sequence homology between DvE3 and
DvE6, this is consistent with the more potent m-fluoro analogue
4 against DvE3 also having (S) stereochemistry as described
elswhere.
28
An approximately tenfold range in activity for m-substituents
is also seen for DvE3 (pIC50 6.47.5) and DvE5 (pIC50 7.17.8)
with antagonist activities generally being greater than those
observed for DvE6. The SAR is idiosyncratic suggesting that
multiple low energy binding conformations may be possible.
As seen with the para-substituents, the DvE8 SAR essentially
tracks the DvE6SAR.
The m-CN analogue 32 shows an approximate 0.71.4 log
selectivity for DvE5 (pIC50 7.4) over the other Dv integrins. The
m-CF3 analogue 33S is the most potent antagonist against DvE6
(pIC50 7.1) and equipotent against DvE3, DvE5 and DvE8 (pIC50
7.0, 7.2 and 6.9). Meta-substitution is clearly highly influen-
tial on the selectivity profile and further work is ongoing.
Given the impact of mono aryl substitution on potency and
selectivity, we decided to explore also the impact of di-
substitution because if there are multiple binding pockets in
this region of the active site, then synergistic effects might be
observed. As the meta position had proved most sensitive we
preserved substitution at this position whilst varying the posi-
tion of the second substituent selecting analogues (35χ43)
which could be prepared from readily available starting mate-
rials.
A greater range in potency was seen with di-substituted ana-
logues compared with mono substituted analogues. Prepara-
tion of substitution patterns of dichloro analogues gives an
interesting range of selectivity profiles. The 2,3-dichloro 35
shows micromolar potency for DvE5 and ten-fold selectivity
over the other Dv integrins. The 3,4-dichloro 36 and the 3,5-
dichloro 37 restore DvE6 activity (pIC50 6.7 and 6.8 respective-
ly) with the 3,5 analogue 37 being a pan Dv antagonist. Sepa-
ration of the 3,5-Cl2 enantiomers
29
gave DvE6 pIC50 activities of
6.8 (37E2) and 5.2 (37E1) with 37E2remaining predominantly
a pan antagonist.
As expected, the known 3,4-methylenedioxy analogue 42
17
has
approximately nanomolar potency and greater than ten-fold
selectivity for DvE3 and DvE5 over DvE6 and DvE8; it also has
increased potency by 0.60.7 log units over the 3,4-dimethoxy
substituents 41 which is less selective for DvE3 and DvE5. The
presence of the oxygens is important as both the correspond-
ing indane 39 and 3,4-dimethyl substituents 38 are almost a
log unit less potent against DvE3 and DvE5 and are also less se-
lective. The same applies to the 3,4-dichloro analogue 36.
The 3-trifluoromethyl-4-chloro analogue 43 is also a pan Dv
antagonist with the more active enantiomer 43E1
29
having a
similar profile.
Presented here are SAR studies of a series of integrin antago-
nists against DvE3, DvE5, DvE6 and DvE8. Although 4 and 42
have previously been described as DvE3 antagonists,17 the stud-
ies described here show a more detailed picture of their profile
with both compounds potent against DvE3 but also being equi-
potent against DvE5. The SARs presented here clearly show
that by simple variation of the position and nature of the aryl
substituent, the cell adhesion potency against DvE6 can be in-
creased and, comparatively, potency against DvE3 and DvE5
reduced. Comparison of the lead compounds described here
(e.g. 33S and 43E1) with the standards 1 and 3 from the litera-
ture (cf. Figure 1) show they have similar DvE6 activity but
with structural features perhaps more commensurate with oral
bioavailability properties. Their lipophilicities are reasonable
(chrom. logD values of 2.72 for 33S and 3.28 for 43E1) and
they possess good permeability and solubility (data not
shown). Indeed analogues of these compounds prepared by
Merck have been shown to have good oral bioavailability in
dog.
17,28
4Table 1. Activity of aryl substituted analogues in Dv integrincell adhesion assays.a
Comp. R DvE6 cell
pIC50
DvE3 cell
pIC50
DvE5 cell
pIC50
DvE8 cell
pIC50
Chrom.
logDb
Partial selectivityc for...
15 H 5.7 7.0 7.1 6.1 1.56 DvE3 and DvE5
16 2-F 6.0 6.5 7.0 5.4 1.88
17 2-Cl <5.0 5.7 5.8 <5.0 1.92
18 2-Me 6.4 7.3 7.7 5.9 1.85 DvE3 and DvE5
19 2-OMe <5.0 6.3 6.3 <5.0 1.83 DvE3 and DvE5
4 3-F 6.1 7.5 7.8 5.8 1.92 DvE3 and DvE5d
20 3-Cl 6.6 7.1 7.6 6.3 2.30
21 3-CH3 6.4 6.8 7.3 6.2 1.95
22 3-OMe 6.5 7.4 7.2 6.3 1.66 DvE3 and DvE5
23 4-F 6.3 7.0 7.2 6.3 1.75
24 4-Cl 6.4 6.9 6.9 6.2 2.14
25 4-Me 6.1 7.4 7.0 6.0 1.97 DvE3 and DvE5
26 4-OMe 6.3 7.6 7.3 6.3 1.64 DvE3 and DvE5
27 4-CN 6.4 7.1 6.4 6.1 1.47 DvE3
28 4-CF3 6.2 6.6 6.5 6.1 2.72 pan
29 4-OCF3 6.2 6.8 6.3 6.1 2.85
30 4-SO2Me 6.2 6.9 6.4 6.1 1.08
31 4-Ph 6.4 7 6.2 6.5 3.10
32 3-CN 6.6 6.7 7.4 6.0 1.67 DvE5
33 3-CF3 7.0 6.7 7.4 6.8 2.73
33S (S)-3-CF3 7.1 7.0 7.2 6.9 2.72 pan, DvE6 lead
33R (R)-3-CF3 5.2 <5
d 5.7 d <5d 2.61
34 3-OCF3 6.7 6.4 7.1 6.6 3.11
35 2,3-Cl2 5.1 5.4 6.3 5 2.73 DvE5
36 3,4-Cl2 6.7 7.3 7.0 6.7 2.62 pan
37 3,5-Cl2 6.8 6.4 6.7 6.6 2.93
37E1 3,5-Cl2 (Ent. 1) 5.2
d <5d 6.0d <5 2.97
37E2 3,5-Cl2 (Ent. 2) 6.8 6.9 6.6 7.0 2.80 pan
38 3,4-Me2 6.7 7.2 7.2 6.3 2.29
39 3,4-CH2CH2CH2 6.8 6.9 7.1 6.4 2.52
40 3,5-Me2 6.3 6.4 6.4 6.2 2.43
41 3,4-(OMe)2 6.5 7 7.2 6.4 1.37
42 3,4-OCH2O- 6.6 7.8 7.9 6.1 1.47 DvE3 and DvE5d
43 3-CF3-4-Cl 7.0 6.5 6.9 6.6 3.1 pan
43E1 3-CF3-4-Cl (Ent. 1) 7.2 6.8 7.2 6.9 3.28 pan, DvE6 lead
43E2 3-CF3-4-Cl (Ent. 2) <5 5.8
e 6.2e <5e 3.25
aAll compounds racemic unless shown. All biological data are means from at least n = 2 and within ± 0.42 of the mean. pIC50 values
are the negative log of the IC50. The lower limit of the assays is around pIC50
5; bChromatographic logD  see reference 21; cDefined as
at least a 0.7 log difference in pIC50 values between the integrins in question; dSee reference 17; eValues are n=1.
Although a crystal structure of DvE6 is currently not available,
a homology model is available
30
and the DvE3 crystal structure
has been described.
31
From the latter, it is known that the
RGD motif (or ligand mimetic) binds at the interface between
the Dv and the E3 (or E6) subunits with the arginine (or mimet-
ic) binding to the Dv unit and the aspartic acid (or mimetic)
5binding to the E3 (or E6) subunit. There is considerable se-
quence similarity between the E3 and E6 subunits so the gross
topology is also likely to be similar. Based on this, an extend-
ed conformation for these ligands in DvE6 is likely to be the
conformation for antagonism and is also consistent with why
small differences in aryl group substitution might have the
profound impact on the selectivity between the different Dv
integrins observed.
Further studies to improve DvE6 potency are underway. Clear-
ly sufficient potency is required to drive an antifibrotic re-
sponse at a realistic clinical dose but a compromise may be
required between the ideal potency and ideal selectivity. Alt-
hough our focus here is IPF, a pan Dv antagonist has recently
been reported
32
as being efficacious in a number of models of
fibrotic diseases (see supporting information).
Described here are SAR relationships against DvE3, DvE5, DvE6
and DvE8 with the aim of ultimately identifying an orally bioa-
vailable selective and potent DvE6 for treating IPF. The lead
compounds 33S and 43E1 have been derived from DvE3 antag-
onists to pan Dv antagonists with antagonisms around pIC50 7
(100 nM). This has been achieved whilst maintaining physi-
cochemical properties commensurate with oral bioavailability.
Compounds which are partially selective for DvE5 have also
been identified. Further studies will be reported in due course.
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